Gene therapy for cardiovascular disorders: Is there a future?

Annals of the New York Academy of Sciences

Volumn 953, Issue , 2001, Pages 31-42

  Metcalfe, Beverly L ^a   Sellers, Kathleen W ^a   Jeng, Michael Jing Ren ^a   Huentelman, Matthew J ^a   Katovich, Michael J ^b   Raizada, Mohan K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cardiovascular disorders; Gene therapy; Heart failure; Hypertension; Ischemia; Restenosis; Thrombosis; Viral vectors

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANGIOTENSIN 2 RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED DNA; DRUG VEHICLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KALLIKREIN; LIPOSOME; NITRIC OXIDE SYNTHASE; OLIGONUCLEOTIDE; PEPTIDE HORMONE; PREPROCALCITONIN GENE RELATED PEPTIDE; RECOMBINANT THROMBOPLASTIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

CARDIOVASCULAR DISEASE; CHIMERAPLASTY; CONFERENCE PAPER; EPIDEMIC; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TECHNOLOGY; GENE THERAPY; GENETIC CODE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MULTIGENE FAMILY; NONHUMAN; PATHOPHYSIOLOGY; RESTENOSIS; THROMBOSIS;

EID: 0035690159     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb11358.x     Document Type: Conference Paper

References (54)

1. Direct gene transfer into mouse muscle in vivo
2. The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease
3. Nonviral vectors in the new millennium: Delivery barriers in gene transfer
4. Prevention of restenosis using the gene for cecropin complexed with DOCSPER liposomes under optimized conditions
5. Recent advances, prospects, and problems in designing new strategies for oligonucleotide and gene delivery in therapy
6. Gene therapy using HVJ-liposomes: The best of both worlds?
7. Gene therapy - Promises, problems, and prospects
8. Production of first generation adenovirus vectors: A review
9. Improvements in adenoviral vector technology: Overcoming barriers for gene therapy
10. Adeno-associated virus vectors for gene therapy: More pros than cons?
11. Gene delivery and gene therapy with herpes simplex virus-based vectors
12. Use of retroviral vectors for gene transfer and expression
13. Retroviral vectors
14. Development of lentiviral vectors for gene therapy for human diseases
15. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B 1 and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery
16. Prevention of restenosis by gene therapy
17. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product
18. p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion
19. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene
20. In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI
21. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels
22. Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model
23. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model
24. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries
25. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor
26. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure
27. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats
28. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats
29. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats
30. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats
31. Antisense oligonucleotides strategy in the treatment of hypertension
32. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense
33. Losartan versus gene therapy: Chronic control of high blood pressure in spontaneously hypertensive rats
34. Inability to induce hypertension in normotensive rat expressing AT(1) receptor antisense
35. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy
36. Gene therapy attenuates the elevated blood pressure and glucose intolerance in an insulin-resistant model of hypertension
37. Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA
38. Angiotensin I-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR
39. Adenoviral gene transfer of basic fibroblast growth factor promotes angiogenesis in rat brain
40. Gene transfer of calcitonin gene-related peptide prevents vasoconstriction after subarachnoid hemorrhage
41. Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery after experimental subarachnoid hemorrhage
42. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
43. Gene therapy for coronary artery disease
44. Gene therapy in heart disease
45. Gene therapy for treatment of cerebral ischemia using defective herpes simplex viral vectors
46. Decoy administration of NF-kappaB into the subarachnoid space for cerebral angiopathy
47. Heat shock protein 70 gene transfection protects mitochondrial and ventricular function against ischemia-reperfusion injury
48. Prospects for gene therapy for heart failure
49. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure
50. Direct intra-cardiomuscular transfer of beta2-adrenergic receptor gene augments cardiac output in cardiomyopathic hamsters
51. In vivo protein transduction: Delivery of a biologically active protein into the mouse
52. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors
53. Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty